-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fusobacterium is named because of the sharp fusiform ends of the bacteria
.
The normal flora that exists in the oral cavity, upper respiratory tract, intestinal tract and urinary system of humans and animals is mostly in the oral cavity
.
Fusobacterium is named because of the sharp fusiform ends of the bacteria
.
The normal flora that exists in the oral cavity, upper respiratory tract, intestinal tract and urinary system of humans and animals is mostly in the oral cavity
.
Among them, Fusobacterium nucleatum (Fn) is a gram-negative obligate anaerobic bacterium, which mainly colonizes the human oral cavity
.
Recent studies have shown that Fusobacterium nucleatum can accumulate in colorectal cancer tissues and affect multiple stages of colorectal cancer progression, including promoting tumor cell proliferation and tumor immune escape, recurrence, and chemotherapy resistance
.
Many studies have shown that Fusobacterium nucleatum in colorectal cancer (CRC) is a cancer-promoting "bad" bacteria that can enhance the chemotherapy resistance of CRC and suppress immunity
.
Epidemiological investigation results also show that the enrichment of Fusobacterium nucleatum in tumors can lead to colorectal tumors: high abundance of Fusobacterium nucleus is associated with poor prognosis of patients; cancer recurrence may be partly due to Fusobacterium nucleus Can promote colorectal cancer tissue to develop resistance to chemotherapy
.
The team of Professor Qin Huanlong of Shanghai Tenth People's Hospital affiliated to Tongji University published a new study on Signal Transduction and Targeted Therapy, but found that Fusobacterium nucleatum may also have a "good" side for the treatment of CRC! Although, it itself can promote chemotherapy resistance and suppress immunity
.
However, it may become a Trojan horse and enhance the effect of anti-PD-L1 immunotherapy
.
Fn can induce a differentiated immune response in different states of microsatellite instability (MSI)
.
Patients with high levels of F.
nucleatum were more responsive to PD-1 blockade than those with low levels of F.
nucleatum.
Researchers analyzed 41 colorectal cancer (CRC) patients treated with PD-1 inhibitors and found that they had nucleated Patients with higher levels of Fusobacterium (Fn) have better therapeutic effects; at the same time, in a variety of mouse models, it has also been confirmed that Fn can enhance the anti-tumor effect of PD-L1 blockade therapy, prolong survival, and make PD-L1 blocks the response of mice that do not respond to treatment
.
In order to further clarify the mechanism, the study found that Fn can activate the STING signaling pathway to induce CRC cells to express PD-L1, and increase the accumulation of IFN-γ+CD8+ tumor infiltrating lymphocytes, thereby increasing the sensitivity of tumors to PD-L1 blockade therapy
.
At the same time, in the CRC organoid model, it was also found that exposure to Fn can improve the response to PD-L1 blockade therapy
.
The results of this study reveal the new role of Fusobacterium nucleatum in immunotherapy of CRC and provide potential biomarkers for clinical prediction of the efficacy of PD-1/PD-L1 blockade therapy
.
Reference materials Gao Y, Bi D, Xie R, Li M, Guo J, Liu H, Guo X, Fang J, Ding T, Zhu H, Cao Y, Xing M, Zheng J, Xu Q, Xu Q, Wei Q, Qin H.
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
Signal Transduct Target Ther.
2021 Nov 19;6(1):398.
doi: 10.
1038/s41392-021-00795-x | Swagpp click "read the original text" below to download the Metz Medical APP
.
The normal flora that exists in the oral cavity, upper respiratory tract, intestinal tract and urinary system of humans and animals is mostly in the oral cavity
.
Fusobacterium is named because of the sharp fusiform ends of the bacteria
.
The normal flora that exists in the oral cavity, upper respiratory tract, intestinal tract and urinary system of humans and animals is mostly in the oral cavity
.
Among them, Fusobacterium nucleatum (Fn) is a gram-negative obligate anaerobic bacterium, which mainly colonizes the human oral cavity
.
Recent studies have shown that Fusobacterium nucleatum can accumulate in colorectal cancer tissues and affect multiple stages of colorectal cancer progression, including promoting tumor cell proliferation and tumor immune escape, recurrence, and chemotherapy resistance
.
Many studies have shown that Fusobacterium nucleatum in colorectal cancer (CRC) is a cancer-promoting "bad" bacteria that can enhance the chemotherapy resistance of CRC and suppress immunity
.
Epidemiological investigation results also show that the enrichment of Fusobacterium nucleatum in tumors can lead to colorectal tumors: high abundance of Fusobacterium nucleus is associated with poor prognosis of patients; cancer recurrence may be partly due to Fusobacterium nucleus Can promote colorectal cancer tissue to develop resistance to chemotherapy
.
The team of Professor Qin Huanlong of Shanghai Tenth People's Hospital affiliated to Tongji University published a new study on Signal Transduction and Targeted Therapy, but found that Fusobacterium nucleatum may also have a "good" side for the treatment of CRC! Although, it itself can promote chemotherapy resistance and suppress immunity
.
However, it may become a Trojan horse and enhance the effect of anti-PD-L1 immunotherapy
.
Fn can induce a differentiated immune response in different states of microsatellite instability (MSI)
.
Patients with high levels of F.
nucleatum were more responsive to PD-1 blockade than those with low levels of F.
nucleatum.
Researchers analyzed 41 colorectal cancer (CRC) patients treated with PD-1 inhibitors and found that they had nucleated Patients with higher levels of Fusobacterium (Fn) have better therapeutic effects; at the same time, in a variety of mouse models, it has also been confirmed that Fn can enhance the anti-tumor effect of PD-L1 blockade therapy, prolong survival, and make PD-L1 blocks the response of mice that do not respond to treatment
.
In order to further clarify the mechanism, the study found that Fn can activate the STING signaling pathway to induce CRC cells to express PD-L1, and increase the accumulation of IFN-γ+CD8+ tumor infiltrating lymphocytes, thereby increasing the sensitivity of tumors to PD-L1 blockade therapy
.
At the same time, in the CRC organoid model, it was also found that exposure to Fn can improve the response to PD-L1 blockade therapy
.
The results of this study reveal the new role of Fusobacterium nucleatum in immunotherapy of CRC and provide potential biomarkers for clinical prediction of the efficacy of PD-1/PD-L1 blockade therapy
.
Reference materials Gao Y, Bi D, Xie R, Li M, Guo J, Liu H, Guo X, Fang J, Ding T, Zhu H, Cao Y, Xing M, Zheng J, Xu Q, Xu Q, Wei Q, Qin H.
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
Signal Transduct Target Ther.
2021 Nov 19;6(1):398.
doi: 10.
1038/s41392-021-00795-x | Swagpp click "read the original text" below to download the Metz Medical APP
